---
document_datetime: 2025-12-12 10:16:16
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/prevymis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: prevymis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5666887
conversion_datetime: 2025-12-27 09:05:42.784192
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## PREVYMIS

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 05/12/2025                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000304418                      | Update of the package leaflet with revised contact details of local representative and update of the Use of Instructions to remove the word 'child' from 'step 10. Take all of the PREVYMIS mixture' under 'Mix with soft food'.                                                                                                                                                                                                                                                                                                  |            |          |                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000262178 | This was an application for a group of variations. B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.b The implementation of the change requires further supportive data - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.g Addition or replacement (excluding biological or immunological product) of a specification parameter with its corresponding test method as a result of a safety or quality issue - Accepted | 15/04/2025 | Annex II |                                                                                                                                                                                                                                                                                                     |
| PSUR / EMA/PSUR/0000248461            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |          | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing letermovir remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). Issues to be addressed in the next PSUR or as a |

<div style=\"page-break-after: always\"></div>

| post-authorisation measure (PAM) or as part of a subsequent RMP update   |
|--------------------------------------------------------------------------|